The UK and US have concluded a important commercial pact that will preserve no tariffs on UK medicine exports going into the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase spending on medicines through the public health system. This move ensures that tariffs on these crucial goods will be held at nothing for a timeframe of the next three years.
This development is in response to earlier threats to significantly raise import taxes on branded drug imports, with figures floated up to 100%.
"This deal between the Britain strengthens the international landscape for new treatments and establishes long-overdue balance to U.S.–U.K. pharmaceutical trade," a statement noted.
Economic Importance
Drugs represent one of the UK's largest export categories to the US, which is easily the primary market for major British pharmaceutical firms.
Export figures reveal that in the year to the end of September, the UK shipped pharmaceutical products totaling billions to the US. This figure made up a significant portion of British export trade in that period.
"This deal safeguards work, stimulates capital expenditure and sets the stage for the UK to become a global hub for life sciences," a government official commented.
Specific NHS Changes
The deal entails several key pledges from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to double overall NHS spending on treatments from 0.3% of GDP to 0.6% over the coming ten years.
- Rebate Cap: The sum manufacturers must refund to the NHS to stay within budget will be limited at 15%. In the past, rebates were more than 20%.
Broader Context
The pact comes amid a ongoing dispute between the pharmaceutical industry and the ministers over spending levels and regulatory access.
The disagreement were exacerbated by claims that US patients were paying a premium for the same drugs than consumers in the other developed nations.
In recent months, several significant pharmaceutical investments in the UK have been halted or scrapped, while major funding commitments have been directed toward US facilities.
A senior figure publicly accepted that the NHS must spend more on treatments, noting that its expenditure on drugs had declined as a proportion of its resources over the last ten years.
